Drug makers finally targeting niche diseases

This is a welcome development, and in line with an ongoing Fordcastle project around developing a personalized medical research program for client. As it becomes exponentially cheaper to deliver highly targeted insights and solutions for small populations, we'll be seeing more niche biotech on behalf of individuals and families that can then be widened to deliver gains to society.  

Drug makers see gains in broadening their reach - Boston.com:

After years of focusing on common diseases afflicting mostly middle-class and affluent patients, drug companies are devoting more resources to rare disorders, illnesses that are prevalent in the developing world, and medical conditions that affect minority populations in rich countries. The trend, which is slowly gaining momentum, is being driven by several factors, including the emergence of ?personalized?? medicines based on an individual?s genetic makeup, and the success of companies such as Genzyme Corp. that already specialize in making drugs to treat rare diseases.